South Carolina is currently home to 1173 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
StrokeNet Thrombectomy Endovascular Platform
NCT06289985
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Medical University of South Carolina University Hospital, Charleston, South Carolina
Conditions: Ischemic Stroke
Register for Updates
Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students
NCT06047041
Recruiting
This study will assess how different types of training and support influence the way that school staff understand, and respond to, the mental and behavioral health needs of middle school students. Researchers will work with middle schools using a developed screening system (called the Early Identification System; EIS) and compare how staff and student outcomes change when schools receive two different types of training and support: 1) standard onboarding/training versus 2) participating in profe... Read More
Gender:
ALL
Ages:
Between 10 years and 99 years
Trial Updated:
06/16/2025
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Mental Health Issue
Register for Updates
Cold Atmospheric Plasma Device Extension Study
NCT05937672
Recruiting
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearan... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
06/16/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Verruca Vulgaris, Molluscum Contagiosum
Register for Updates
Wrist Extensor MEP Up-conditioning for Individuals With Incomplete Spinal Cord Injury
NCT05321017
Recruiting
The purpose of this study is to examine the relationship between common clinical assessments and measurements of the function of brain-spinal cord-muscle connections, and to examine the effects of training a brain-spinal cord-muscle response in individuals with incomplete spinal cord injury. A transcranial magnetic stimulator (TMS) is used for examining brain-to-muscle pathways. This stimulator produces a magnetic field for a very short period of time and indirectly stimulates brain cells with l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Spinal Cord Injuries, Quadriplegia
Register for Updates
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Hollings Cancer Center, Charleston, South Carolina
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/13/2025
Locations: Clinical Research of Rock Hill, Rock Hill, South Carolina
Conditions: Asthma
Register for Updates
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study dur... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
06/13/2025
Locations: Coastal Pediatric Associates - Charleston- Site Number : 8400014, Charleston, South Carolina
Conditions: Pneumococcal Immunization
Register for Updates
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
NCT05865535
Recruiting
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: MUSC Hollings Cancer Center, Charleston, South Carolina
Conditions: Cachexia
Register for Updates
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Sunpharma site no 31, Greenville, South Carolina
Conditions: Psoriatic Arthritis
Register for Updates
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
NCT05268614
Recruiting
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/12/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates